December 5, 2020 05:05 PM ESTUpdated December 7, 07:29 AM
R&D

#ASH20 In a mul­ti­ple myelo­ma show­down, Re­gen­eron march­es out new PhI da­ta for its BC­MA bis­pe­cif­ic

Nicole DeFeudis

Editor

Af­ter kick­ing off a mul­ti­ple myelo­ma ri­val­ry with Bris­tol My­ers Squibb at last year’s ASH, Re­gen­eron is back with an up­dat­ed safe­ty and dura­bil­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Up­dat­ed: Phar­ma is next in line as Trump says tar­iffs are com­ing 'very short­ly'

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Drug pric­ing watch­dog ICER of­fers ways to in­crease obe­si­ty drug ac­cess

Could Kennedy's FDA cuts trig­ger an ob­scure claw­back pro­vi­sion for in­dus­try user fees?

Fir­ings of HH­S' pro­ba­tion­ary work­ers can pro­ceed, ap­peals court says

Rare dis­ease hub at CDER and CBER faces new re­al­i­ty with staff crunch

A service from the Financial Times